The SARS-CoV-2 pandemic still represents a threat for immunosuppressed and hematological malignancy (HM) bearing patients. causing increased morbidity and mortality. Given the low anti-SARSCoV-2 IgG titers post-vaccination. the COVID-19 threat prompted the prophylactic use of engineered anti-SARS-CoV-2 monoclonal antibodies. https://smokeysmountainfurnitureoutlets.shop/product-category/chest/